echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > National Development and Reform Commission reviews the end of unified price reduction of traditional Chinese medicine to start the countdown?

    National Development and Reform Commission reviews the end of unified price reduction of traditional Chinese medicine to start the countdown?

    • Last Update: 2014-02-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2014-02-21 source: since last year, the daily economic news has been widely spread about the comprehensive price reduction of Chinese patent medicine, but the rumor of "landing" in last year's year has not landed yet Recently, the drug price evaluation center of the national development and Reform Commission announced that the pre evaluation meeting of five kinds of drug experts, such as Chinese patent medicine gynecology, had been held in Beijing The reporter of the daily economic news learned that this was interpreted by the market as a signal of unified price reduction or countdown of traditional Chinese medicine According to the news of the drug price evaluation center of the national development and Reform Commission on the evening of February 19, the drug price evaluation center of the national development and Reform Commission held a pre evaluation meeting for five kinds of drug experts, such as Chinese patent medicine gynecology, in Beijing , otolaryngology, orthopedics, dermatology in the price review of proprietary Chinese medicine related issues and varieties for discussion and consultation, listen to expert opinions Experts from drug administration, drug testing, hospital clinical and scientific research institutions attended the meeting The end of this review means that the national development and Reform Commission has completed the review of all prices of traditional Chinese medicine, and it has become an important signal for the price adjustment of traditional Chinese medicine to enter the countdown In January 2013, the national development and Reform Commission began to adjust the price of chemical drugs one after another Since then, there has been a continuous trend that the Chinese patent medicine in the medical insurance catalog will be adjusted It has been said that the price adjustment policy will be issued before the end of last year, but until the middle and late February of 2014, the price reduction of Chinese patent medicine has not been implemented Since November 2013, the drug review center of the national development and Reform Commission has intensively carried out 7 rounds of review work, and carried out price review on all traditional Chinese medicines in the medical insurance catalog The market people interpreted this as that the price adjustment of Chinese patent medicine is imminent Since 2010, the national development and Reform Commission has carried out multiple rounds of price cuts for chemicals, with an average drop of 17% - 41%, involving antibiotics, circulation, nerves, hormones, digestion, anti-tumor, immune and blood categories In January 2013, the national development and Reform Commission issued a notice again, deciding to adjust the maximum retail price limit of drugs such as respiratory, antipyretic and analgesic drugs and special drugs from February 1, 2013, involving 20 categories of drugs, more than 400 varieties and more than 700 representative dosage forms, with an average price reduction of 15%, of which the average price reduction of high-priced drugs reached 20% This is the 31st round of drug price reduction launched by the national development and Reform Commission in the past 15 years It should be noted that, in addition to proprietary Chinese medicine, the price adjustment of all categories of chemicals has been completed The decrease determines the market impact The relevant person in charge of the national development and Reform Commission has disclosed that the specific policy for the price adjustment of Chinese patent medicine in the next stage is still being formulated, and it is expected that the price will "rise or fall" For some Chinese patent medicines with relatively rapid price rise of raw materials, the price may rise to a certain extent According to the practice of Western medicine price adjustment, the price of a batch of drugs will be reduced after the evaluation center completes the price evaluation The schedule can refer to the previous price reduction process of narcotic drugs and psychotropic drugs - on January 30, 2013, the drug price review center of the national development and Reform Commission carried out the review, and announced the price adjustment on December 30 The review is about two months away from the price adjustment This time, the review center is abnormal It has finished the review of all traditional Chinese medicine, but it has not yet issued the price reduction policy The coming price reduction of Chinese patent medicine is likely to be a unified price adjustment of multiple categories As for the news that Chinese patent medicine may reduce its price, the reporter of "daily economic news" contacted Fang Shuting, President of China Association of traditional Chinese medicine, but he said that there was no clear information at present and would go to further understand the situation Drug price reduction has a direct impact on the operating performance of related pharmaceutical listed companies If there is an exclusive core variety, the impact of price reduction on listed companies can not be underestimated, so the capital market is also very concerned According to the research report issued by Jiang Weina of Everbright Securities [- 2.22% capital research report], the impact of drug price reduction is mainly reflected in 2014 At present, there is a consensus on drug price reduction in the market, and the biggest uncertainty is the judgment of price reduction range From 2012 to 2013, the overall price reduction of chemical drugs is about 17% If the drop of proprietary Chinese medicine is more than 20%, the enterprise performance pressure will be greater If the price reduction is less than 15%, it is good for the pharmaceutical industry Jiang Guangce, chairman of Dechuan medical fund, told the daily economic news that it is not expected that the price reduction of Chinese patent medicine will have a great impact on the whole pharmaceutical sector On the one hand, the price reduction of traditional Chinese medicine has not been implemented yet, and the market is ready to digest this expectation At the same time, the public relations ability of large pharmaceutical enterprises is relatively strong, so the decline of exclusive varieties should be limited  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.